Executive Director, Global Health Economics and Outcomes Research

• Define and own the global HEOR strategy across marketed products and pipeline assets, aligned with corporate and portfolio priorities
• Provide strategic leadership and direction to a global HEOR team, fostering scientific excellence and operational rigor
• Manage external vendors, academic partnerships, and research collaborations to deliver high-quality evidence efficiently
• Lead early value and evidence planning for late-stage and pre-launch assets, including development of global value stories and integrated evidence plans
• Partner with Clinical Development to ensure trial designs, endpoints, and comparators address future HTA and payer requirements, particularly in rare diseases
• Inform Target Product Profiles (TPPs) and access-relevant decision-making during development
• Support global and regional Market Access teams with HEOR inputs for launch planning, pricing strategy, and reimbursement submissions
• Oversee development of global value dossiers, cost-effectiveness models, budget impact analyses, and AMCP/HTA submissions
• Anticipate and address access challenges in key markets, including evidence uncertainty common in rare and ultra-rare indications
• Drive post-launch evidence generation, including real-world evidence (RWE), registries, and long-term outcomes studies, to support label expansions, re-assessments, and sustained reimbursement
• Optimize value demonstration for mature brands through updated economic models, new endpoints, and evolving payer needs
• Monitor changes in global HTA and payer landscapes and proactively adapt evidence strategies
• Ensure integration of patient-reported outcomes (PROs), quality-of-life, caregiver burden, and disease burden data into global evidence strategies
• Collaborate closely with Medical Affairs on publications, scientific exchange, and congress strategy
• Partner with Patient Advocacy and external stakeholders to embed the patient voice in value narratives
• Oversee HEOR publications, abstracts, and presentations at major international congresses (e.g., ISPOR, HTAi, DIA)
• Represent the company in external scientific, policy, and payer-related forums
• Ensure all HEOR activities comply with global regulatory, ethical, and scientific standards

• PhD, DrPH, PharmD, MD, or equivalent advanced degree in Health Economics, Outcomes Research, Public Health, Epidemiology, Health Policy, or related discipline
• Fluent in English
• Minimum 15+ years of commercial experience in the pharmaceutical industry
• Minimum of 10+ years of HEOR experience in pharmaceutical or biotechnology companies, with significant exposure to rare diseases and global roles
• Demonstrated success supporting global launches and pre-launch assets, as well as lifecycle management of marketed products
• Proven experience engaging with HTA bodies and payer stakeholders across major markets (US, EU, UK, Japan)
• Experience leading multicultural teams
• With experience of specialty care products in highly competitive markets
• Proven track record of marketing across multiple stages of a products life cycle
• Successful Global launch experience in specialty and/or rare disease, preferably in the specific therapeutic area
• Strong leadership skills and business acumen
• Demonstrated agility, accountability, sense of urgency and team spirit
• Capability to embark and enroll cross functional stakeholders at all levels of the organizations
• Ability to build strong relationships across cultures, backgrounds and functions
• Can manage complex situations and demonstrated ability to make decisions
• Strong planning and project management skills – can and has successfully driven projects involving several departments and functions
• Ability to convey complex information succinctly & simply (including verbal, written and in presentations)
• Resilience and openness to change
• Complies with Company guidelines and country/industry standards on ethics and compliance and acts as a role model for ethical behavior

Experience in rare diseases market would be a plus